Related Experiment Video

Updated: May 1, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Interleukin-6 receptor rs7529229 T/C polymorphism is associated with left main coronary artery disease phenotype in a

Feng He1, Xiao Teng2, Haiyong Gu3

  • 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. drhefeng@gmail.com.

International Journal of Molecular Sciences
|April 5, 2014
PubMed

Insights

Genetic variants in Interleukin-6 Receptor (IL-6R) rs7529229 may increase susceptibility to severe Left Main Coronary Artery Disease (LMCAD). This finding in a Chinese population suggests a potential genetic link to LMCAD risk.

Area of Science:

  • Genetics
  • Cardiology
  • Immunology

Background:

  • Left Main Coronary Artery Disease (LMCAD) is a severe form of Coronary Artery Disease (CAD).
  • Interleukin (IL) gene polymorphisms are implicated in inflammatory diseases and CAD.
  • Limited research exists on the association between genetic variants and specific CAD phenotypes like LMCAD.

Purpose of the Study:

  • To investigate the association between single nucleotide polymorphisms (SNPs) in IL-related genes and the susceptibility to LMCAD compared to more peripheral CAD (MPCAD).
  • To identify specific IL gene variants that may contribute to the LMCAD phenotype.

Main Methods:

  • A hospital-based case-only study involving 402 LMCAD patients and 804 MPCAD patients from a Chinese population.
  • Genotyping of seven IL gene SNPs (IL-1A rs1800587, IL-1B rs16944, IL-6 rs1800796, IL-6R rs7529229, IL-8 rs4073, IL-10 rs1800872, IL-10 rs1800896) using MALDI-TOF MS and LDR.
  • Statistical analysis to compare allele and genotype frequencies between LMCAD and MPCAD groups.

Main Results:

  • The IL-6 Receptor (IL-6R) rs7529229 T/C polymorphism showed a significant association with LMCAD risk.
  • Specifically, the CC or TC/CC genotypes of IL-6R rs7529229 were associated with an increased risk of LMCAD compared to the TT genotype (OR=1.46, p=0.042 for CC; OR=1.31, p=0.037 for CC+TC).
  • No significant associations were found for the other six studied SNPs between LMCAD and MPCAD.

Conclusions:

  • The IL-6R rs7529229 T/C functional SNP may be a contributing factor to LMCAD susceptibility in the Chinese population.
  • Further validation in larger, ethnically diverse populations is necessary to confirm these findings.
  • This study highlights the potential role of specific genetic variations in the pathogenesis of severe CAD phenotypes.

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

915
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81